The Medicines Patent Pool (MPP)’s five-year strategic plan supports its mission of increasing access to, and facilitating the development of, life-saving medicines for low- and middle-income countries. The new strategy calls for renewed efforts to provide better treatment options for people living with HIV, hepatitis C and tuberculosis. Based on the findings of a feasibility study, the plan also recommends the expansion of the MPP model to patented medicines with high medical value, starting with small molecules on the World Health Organization Model List of Essential Medicines.
An estimated two billion people lack access to health products and essential medicines.¹ The vast majority of these people live in low- and middle-income countries (LMICs). Effective and affordable new treatments easily administered in resource-limited settings, fixed-dose combinations (FDCs) with better adherence and tolerability profiles to fight growing resistance and formulations specifically adapted for children, will prolong and save lives.
1 Access to Medicines Index, 2016
2018 – 2022
We will measure our success based on achieving the following five targets by 2022:
More than 20 million people living with HIV in LMICs are treated with MPP-licensed antiretrovirals.
Curative, pangenotypic hepatitis C treatments are available for ≤ US$ 50 per person from quality-assured suppliers in licensed countries.
Shortened all-oral regimen with the potential for use in drug-resistant and drug-susceptible tuberculosis is licensed to MPP.
MPP has licensed patented medicines that are on the WHO EML or are likely to be added in the future.
The MedsPaL database incorporates up-to-date reliable intellectual property status information on all patented essential medicines for all LMICs.
How MPP’s Strategic Plan Contributes To International Goals
International HIV Targets
Expand treatment to reach 30 million people living with HIV
by 2025. End AIDS by 2030.
License and accelerate introduction of new and approved antiretrovirals, including paediatric formulations and delivery systems such as long-acting injectables. Explore voluntary licensing of novel products for pre-exposure prophylaxis (PrEP) and emerging technologies for an HIV cure.
International Hepatitis C Targets
Eliminate viral hepatitis as a major public health threat by 2030. Reduce hepatitis C infections by 80% and deaths by 65%.
Facilitate affordable access to direct-acting antivirals with the
potential of working across all strains of the virus.
International Tuberculosis Targets
Reduce TB deaths by 95% between 2015 and 2035.
End tuberculosis by 2030.
License new drugs, drug candidates and regimens that can be used to improve the standard of care for both drug-resistant and drug-susceptible TB.
International Targets for Universal Health Coverage and Essential Medicines
Achieve Universal Health Coverage, including […] access to safe, effective, quality and affordable essential medicines and vaccines for all.
Expand our mandate beyond HIV, hepatitis C and TB, initially
into patented small molecules that are listed on the WHO
EML. License medicines with strong potential for future
inclusion in the EML in view of their clinical benefits and
potential for public health impact, including new antimicrobials.
As public health priorities shift, so too must we adapt to deliver
results and fulfill our overall mission of ensuring equitable access to medical treatment and health technologies.
The following cross-cutting initiatives will support the organisation’s long-term viability and ensure the successful implementation of our strategy:
How MPP Licensing Approaches Will Evolve Over The Next Five Years